Cognition Therapeutics (CGTX) Competitors $0.72 -0.05 (-5.90%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.73 +0.00 (+0.55%) As of 01/31/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CGTX vs. EDIT, ANRO, ENTA, CABA, XBIT, ATOS, ZURA, MIST, CRDL, and MGXShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Editas Medicine (EDIT), Alto Neuroscience (ANRO), Enanta Pharmaceuticals (ENTA), Cabaletta Bio (CABA), XBiotech (XBIT), Atossa Therapeutics (ATOS), Zura Bio (ZURA), Milestone Pharmaceuticals (MIST), Cardiol Therapeutics (CRDL), and Metagenomi (MGX). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Editas Medicine Alto Neuroscience Enanta Pharmaceuticals Cabaletta Bio XBiotech Atossa Therapeutics Zura Bio Milestone Pharmaceuticals Cardiol Therapeutics Metagenomi Cognition Therapeutics (NASDAQ:CGTX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. Do insiders and institutionals believe in CGTX or EDIT? 43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 20.8% of Cognition Therapeutics shares are held by company insiders. Comparatively, 1.9% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, CGTX or EDIT? Cognition Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Does the MarketBeat Community prefer CGTX or EDIT? Editas Medicine received 292 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Cognition Therapeutics an outperform vote while only 53.23% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformCognition TherapeuticsOutperform Votes2170.00% Underperform Votes930.00% Editas MedicineOutperform Votes31353.23% Underperform Votes27546.77% Do analysts prefer CGTX or EDIT? Cognition Therapeutics currently has a consensus price target of $8.30, indicating a potential upside of 1,047.99%. Editas Medicine has a consensus price target of $7.00, indicating a potential upside of 434.35%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cognition Therapeutics is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Editas Medicine 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07 Is CGTX or EDIT more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. Editas Medicine's return on equity of -80.13% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -150.93% -100.82% Editas Medicine -340.96%-80.13%-50.99% Does the media favor CGTX or EDIT? In the previous week, Cognition Therapeutics had 4 more articles in the media than Editas Medicine. MarketBeat recorded 11 mentions for Cognition Therapeutics and 7 mentions for Editas Medicine. Cognition Therapeutics' average media sentiment score of 0.77 beat Editas Medicine's score of -0.16 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, CGTX or EDIT? Cognition Therapeutics has higher earnings, but lower revenue than Editas Medicine. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$25.79M-$0.97-0.75Editas Medicine$78.12M1.38-$153.22M-$2.56-0.51 SummaryCognition Therapeutics beats Editas Medicine on 11 of the 18 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.61M$3.05B$5.58B$9.12BDividend YieldN/A1.84%5.31%3.99%P/E Ratio-0.7536.8280.0317.24Price / SalesN/A319.021,259.7283.26Price / CashN/A190.0245.9637.70Price / Book0.954.125.124.70Net Income-$25.79M-$40.99M$111.40M$224.47M7 Day Performance-4.10%-0.43%2.30%-0.19%1 Month Performance3.09%0.94%3.13%0.57%1 Year Performance-68.43%-1.69%24.60%20.35% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics3.8833 of 5 stars$0.72-5.9%$8.30+1,048.0%-68.1%$31.61MN/A-0.7520Short Interest ↓Analyst RevisionNews CoverageGap UpEDITEditas Medicine4.4093 of 5 stars$1.41+2.2%$7.00+396.5%-81.4%$116.40M$78.12M-0.55230Short Interest ↑Gap DownANROAlto Neuroscience1.4602 of 5 stars$4.31-8.4%$20.00+364.5%N/A$116.13MN/A0.00N/AENTAEnanta Pharmaceuticals4.6099 of 5 stars$5.30-4.2%$17.25+225.5%-57.9%$112.31M$67.64M-0.97160Upcoming EarningsCABACabaletta Bio2.9988 of 5 stars$2.30-8.2%$24.38+962.1%-88.3%$112.18MN/A-1.0750Gap DownXBITXBiotech0.5977 of 5 stars$3.64-0.3%N/A-24.6%$110.95M$4.01M-3.37100ATOSAtossa Therapeutics1.1504 of 5 stars$0.87-6.3%$7.00+702.5%-1.4%$109.74MN/A-3.978Analyst ForecastAnalyst RevisionNews CoverageZURAZura Bio3.2319 of 5 stars$1.66-3.5%$15.80+851.8%-34.0%$108.38MN/A0.003MISTMilestone Pharmaceuticals2.4282 of 5 stars$2.02-1.5%$13.00+543.6%+23.1%$107.73M$1M-2.4930Short Interest ↑Analyst RevisionNews CoverageCRDLCardiol Therapeutics2.0032 of 5 stars$1.29-11.6%$8.75+578.3%+15.6%$106.57MN/A-3.3120Analyst ForecastShort Interest ↑News CoverageGap DownMGXMetagenomi1.7869 of 5 stars$2.77-6.7%$16.67+501.7%N/A$103.65M$44.76M0.00236 Related Companies and Tools Related Companies Editas Medicine Competitors Alto Neuroscience Competitors Enanta Pharmaceuticals Competitors Cabaletta Bio Competitors XBiotech Competitors Atossa Therapeutics Competitors Zura Bio Competitors Milestone Pharmaceuticals Competitors Cardiol Therapeutics Competitors Metagenomi Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGTX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
